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Naka and Nobuaki Kaibara
First Department of Surgery, Faculty of Medicine, Tottori University, Yonago 683-0826, Japan
Postoperative delirium has in recent years been a common complication which can
interfere with the recovery of patients after surgery.  Unfortunately there is still no
medical procedure available which can completely prevent the occurrence of
postoperative delirium.  Haloperidol is a psychopharmacological agent that has been
used to treat the delirium and agitation, especially in geriatric patients.  To assess the
effectiveness and safety of the use of haloperidiol for the reduction of postoperative
delirium, we performed a randomized, comparative clinical study in which 78 patients
who underwent gastrointestinal surgery received either 5 mg of haloperidol
intravenously postoperatively at 21:00 for 5 consecutive days, or normal saline with the
same schedule.  Postsurgical evaluation revealed the incidence of postoperative delirium
to be only 10.5% (4 of 38 patients) in the group receiving haloperidol treatment,
compared to 32.5% (13 of 40 patients) in the saline treatment group.  No significant
neuroleptic side effects were seen in any of the patients.  These results suggest that daily
postoperative administration of haloperidol can reduce the occurrence of postoperative
delirium safely.
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Delirium, defined as an acute disorder of
cognition, wakefulness and attention, has been
recognized as a relatively common postopera-
tive complication in the elderly for some time,
yet, to date, surprisingly little is known about
effective procedures to reduce its occurrence.
Postoperative delirium can result in increased
morbidity, delayed functional recovery and
prolonged hospital stay (Adams et al., 1986).
Therefore, early diagnosis, assessment, prompt
treatment and prevention of postoperative de-
lirium are important objectives for improved
management of elderly surgical patients.
Various hypotheses have been proposed to
explain the pathogenesis of postoperative de-
lirium (Adams et al., 1986).  The responsible
causative factors proposed are preoperative
factors (e.g., aging, pathologic status in the
brain, polypharmacy and drug interactions,
metabolic problems, depression, dementia and
anxiety), intraoperative factors such as type of
surgery and anesthetic drugs and postoperative
factors (e.g., hypoxia, hypocarbia and sepsis).
Although preventative measures against post-
operative delirium have been applied at pre-
operative, intraoperative and postoperative
levels, there is still  little definitive information
available on successful prevention of post-
operative delirium.  The first consideration in
the management of delirium is to find and treat
any underlying organic cause of the presented
state of confusion.  When confusion is evident,
prompt treatment is mandatory.  The first ther-
apy of choice for such cases is an antipsychotic
drug such as haloperidol, which does not pro-
duce hypotension, aggravate diabetes, hepatic
disease or renal disease nor does cause over-
sedation.  The successful use of haloperidol in
such cases makes it an interesting therapeutic
candidate for testing in the prevention of post-
operative delirium in surgical patients.  So far,
there has been no effective prevention of post-
Abbreviation:  DSM, Diagnostic and Statistical Manual of Mental Disorders
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operative delirium with therapy which places
emphasis on medication.  We proposed, there-
fore, that prophylactic administration of halo-
peridol may have a potential application as a
preventative medication for postoperative delir-
ium in surgical patients.
The aim of the current study was to evaluate
the effect and safety of daily postoperative ad-
ministration of haloperidol as a preventative
measure against the development of postopera-
tive delirium, with special attention being paid
to the sleep-wakefulness rhythm, in patients
undergoing gastrointestinal surgery.
Subjects and Methods
Study design and subjects
Ethical comittee approval was obtained before
commencement of this study. Eighty patients
who were scheduled for elective gastrointes-
tinal surgery and admitted to the High and In-
tensive Care Unit at Tottori University Hospital
1 or 2 weeks before the scheduled surgery,
between April 1995 and August 1998, compris-
ed the study population.  After admission, the
patients were interviewed, clinically examined
and subjected to routine laboratory testing.  Be-
fore entering the study, oral consent was requir-
ed from each patient.  The consenting patients
were then randomized into 2 comparative study
treatment groups.  The randomization was con-
ducted by way of a closed envelope system.  Post-
operatively, one group received daily adminis-
tration of haloperidol intravenously, while the
other group was given normal saline.  After the
5th day of the postoperative study treatment, the
2 treatment groups were compared for the inci-
dence of development of postoperative delir-
ium.
Study drug
Haloperidol (Serenase, Dainippon Pharmaceu-
tical, Osaka, Japan) at a dose of 5 mg in 1.0 mL
was administered intravenously daily at 21:00
from the 1st through the postoperative day.
This dose of haroperidol was considered ade-
quate for providing comparable sedation for the
patients.  An equal volume of normal saline for
injection (0.9% NaCl,Otsuka Pharmaceutical,
Tokushima, Japan) was administered by the
same route and schedule as the comparative
group of patients not receiving haloperidol.
Table 1.  Demographic data of patients
Haloperidol group Saline group
Number of patients randomized 40 40
Postrandomization exclusion   2   0
Number of evaluable patients 38 40
Male/female ratio 24/14 26/14
Age* (year) 72.4  ±  8.2 73.1  ±  9.3
Ishemic heart disease   5 (13.2)  8 (20.0)
Hypertension 13 (34.2) 12 (30.0)
Respiratory disease   6 (15.8)  4 (10.0)
Diabetes mellitus   9 (23.7) 12 (25.0)
Liver disease   3 (  7.9)  6 (15.0)
Premorbid cognitive impairment   2 (  5.3)  4 (10.0)
Operation method
Partial gastrectomy 20 (52.6) 23 (57.5)
Total gastrectomy   8 (21.1)  6 (15.0)
Colectomy 10 (26.3) 11 (27.5)
*Mean ± SD.
(  ), percentage.
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Study measurements and evaluation
On the 5th day after surgery, postoperative data
were collected from the patients and their nurs-
ing charts regarding i) cognition, with particular
attention to signs and symptoms of delirium, ii)
use of pain medication and iii) sleep pattern,
with special attention being paid to the sleep-
wakefulness rhythm.  Psychotic diagnoses were
based on the Diagnostic and Statistical Manual
of Mental Disorders (DSM) criteria, DSM-III-R
(American Psychiatric Association, 1987).
Statistical methods
The chi-square test and unpaired student t-test
were used for the statistical analyses of the
results, which are presented as mean ± SD.  A P
value of less than 0.05 was regarded as statis-
tically significant.
Results
During the study, 80 patients scheduled for
gastrointestinal surgery were selected for ran-
dom placing into the 2 treatment groups, 40 into
the haloperidol treatment group and 40 into the
saline control group.  Two patients who had
entered the Intensive Care Unit had to be ex-
cluded before randomization into the study.
The 2 groups were comparable with respect to
baseline criteria (e.g., age, sex, preexisting dis-
Table 2.  The incidence of postoperative de-
lirium in patients with haloperidol  treatment
and saline treatment
Delirious Non-delirious
Haloperidol   4* 34
Saline 13 27
Total 17 61
*P < 0.05 compared to the saline treament patients.
Fig. 1.  Comparison of postoperative sleeping times for saline treatment patients and haloperidol treatment
patients during the day and night during the first 5 postoperative days.  Values are expressed as mean ± SD.
eases, preoperative medications, duration of op-
eration and anesthesia, conditions during anes-
thesia as event of hypotension and hypoxemia,
and intraoperative blood loss).  The demo-
graphic data of the 78 evaluable patients are
listed in Table 1, and there were no statistically
significant demographic differences between
the 2 groups.
Postoperative delirium developed in 17 of
78 patients (21.8%).  Postoperative delirium
began 2 to 4 days after surgery.  Four of the 38
patients (10.5%) were clinically diagnosed as
having postoperative delirium in the study
group.  On the other hand, there were only 13
out of 40 (32.5%) in the control group (Table
2).  Intensity and duration of postoperative
delirial symptoms in the control group were
severe and longer respectively than those in the
study group.  Several other factors (e.g., drugs
and method for postoperative pain control,
hypoxia and infection) were examined and not
found to be associated with the occurrence of
Saline Haloperidol
Day sleep time
Night sleep time
Ti
m
e
(min)
500
400
300
200
100
0
T. Kaneko et al.
182
postoperative delirium.  The patients who dev-
eloped postoperative delirium in the control
group were administered haloperidol immedi-
ately until the delirial symptoms disappeared.
Furthermore, the patients who developed post-
operative delirium in the haloperidol group also
were administered more haloperidol and flunitra-
zepam to control sleep-wakefulness rhythm.
Extrapyramidal side effects have not develop-
ed during the use of this protocol; however, one
patient who was administered haloperidol
developed transient tachycardia, but this did not
substantially interfere with clinical manage-
ment.  No other complications or side effects of
haloperidol use occurred with this protocol.
Between the 2 groups, there was no consider-
able variability in the duration of sleep time in
the day or night.  As a result, the difference in
the average and total time of sleep between the
2 groups was not statistically significant (Fig.
1).  The ratio of sleep time during the day and
night was lower during the use of haloperidol.
In contrast, special attention was paid to the pa-
tients who had developed postoperative deliri-
um, and there was close correlation between the
development of postoperative delirium and de-
privation of sleep rhythm, that is, a short sleep
period during the night and a long sleep period
during the day (Fig. 2).
Discussion
Postoperative delirium and other organic men-
tal syndromes have been frequent and problem-
atic complications, often requiring aggressive
medical management.  Notably cardiotomy and
organ transplantation have appeared to involve
several additive risk factors for the occurrence
of postoperative mental disorders.  Postopera-
tive delirium has also been a common problem
in the field of gastrointestinal surgery.  Un-
familiar surroundings and a sense of alienation
appear to be factors which make patients more
likely to develop postoperative delirium.  We
recently reported that sleep deficiency is likely
to predispose elderly patients to postoperative
delirium and so techniques designed to prevent
sleep deprivation may be of considerable value
in reducing the incidence of postoperative de-
lirium (Kaneko et al., 1997).
Haloperidol, a high-potency antipsychotic
agent, is considered to be the drug of choice for
rapid control of delirium in the critically ill pa-
tient.  Unlike other neuroleptic agents, haloperi-
dol has minimal adverse effects on hemo-
dynamic and respiratory function and does not
aggravate other functions (Fish, 1991).  For this
reason and because the number of elderly pa-
Fig. 2.  Comparison of postoperative sleeping times for delirious and non-delirious patients during the day
and night during the first 5 postoperative days.  Values are expressed as mean ± SD.  There are statistically
significant differences in day and night sleeping times between the delirious and non-delirious group (P <
0.05).
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tients in the operative population who are at risk
in developing postoperative delirium has been
increasing, we felt that haloperidol would be a
suitable candidate medication to test for preven-
tion of postoperative delirium.
Several authors have proposed dosage
guidelines for haloperidol use in the treatment
of acute delirium.  The initial intravenous dose
of haloperidol prescribed for acute delirium
varies with the degree of delirium from only
0.5–2 mg for mild agitation, to 2–5 mg for mod-
erate agitation, to 10–20 mg for severe agitation
(Fish, 1991).  On the other hand, Levenson (1995)
reported a case of delirium following lung
transplantation that required 2,842 mg of
haloperidol intravenously over 4 days.  Though
the maximally tolerated total daily dosage of
haloperidol has not been fully established, it has
been reported to range from 100 mg to over 530
mg (Korp et al., 1985; Levenson, 1995; Kaneko
et al., 1997) and to be as high as 975 mg
(Levenson, 1995).  One case has been reported
in which the intravenous administration of 7.5
mg of haloperidol appeared to cause cardiac
arrest (Menza et al., 1987).  Thus, for the cur-
rent study, it was important to design a protocol
of haloperidol dose and schedule that not only
was potentially therapeutically effective, but
also safe for use in our patient population.  Our
consideration on the safety of our haloperidol
administration protocol depended on several
factors, which included its limitations of use in
an intensive care setting, frequent reassessment
of the patients mental state and careful monitor-
ing for side effects.
As haloperidol is rapidly absorbed after
both oral and intramuscular administration,
rapid control of acute delirium with extreme
agitation is best accomplished with intravenous
delivery.  Moulaert (1989) recommended intra-
venous administration of haloperidol because
the absorption may be erratic when the drug is
given by the intramuscular route.  Moreover,
the pain of intramuscular injection may be add-
ed to the patient’s confusion.  Menza and col-
leagues (1987) also recommended intravenous
administration of haloperidol in the immuno-
suppressed patient due to the lower frequency
of extrapyramidal side effects when it was de-
livered by the intravenous route.  The reason for
this route of administration-related difference
in toxicity is not clear.
The use of haloperidol in physically com-
promised patients with delirium is not entirely
without complications.  As a high-potency
neuroleptic agent, haloperidol has increased
potential to cause extrapyramidal side effect
symptoms.  These effects are not dose-related
and are sudden in onset.  Extrapyramidal symp-
toms are seldom observed with the use of halo-
peridol administered by the intravenous route.
Craven (1990) first reported on the prophy-
lactic intravenous administration of a small
dose of haloperidol 4 times daily, and demon-
strated its effectiveness and safety in the
management of postoperative delirium in lung
transplant recipients.  Although further system-
atic investigation is required to determine the
full potential of clinical effectiveness for halo-
peridol administration in the prevention of pos-
toperative delirium, we have not found any in-
creased frequency of postoperative delirium.
These preliminary findings suggest that this
study protocol of daily postoperative intra-
venous haloperidol administration may be both
an effective and a safe means of preventing the
occurrence of postoperative delirium in patients
undergoing gastrointestinal surgery, partic-
ularly in elderly patients who are at a higher risk
of development of postoperative delirium.
This prospective study is the first systematic
evaluation of the use of prophylactic adminis-
tration of intravenous haloperidol to reduce the
occurrence of postoperative delirium.  The
mechanism by which haloperidol reduces the
occurrence of postoperative delirium is not
clear.  Some studies suggest that actions other
than the blockade of central dopamine receptors
may be responsible for haloperidol’s calming
effect in patients with delirium (Korp et al.,
1985; Tesar and Stern, 1988).  It is also not
clearly understood why prophylactic adminis-
tration of haloperidol reduced the incidence of
postoperative deliriums after gastrointestinal
surgery; we intend to perform further investi-
gation of the optimization of dosage and timing
of haloperidol administration.
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